ACIU
AC Immune SA
NASDAQ · Healthcare · Biotechnology · CH
$2.23
+6.46%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.19
From 52W high−39.86%
Volume77582.00
Market cap$221.22M
P/E (TTM)—
P/S (TTM)10.4x
Div yield—
Key dataNov 4, 2026
Open
$2.19
From 52W high
−39.86%
Volume
77582.00
Market cap
$221.22M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
P/E (TTM)
—
RSI (14)
41.2
MomentumView details →
1D Return
+6.46%
YTD Return
−29.14%
SummaryUpdated Jun 1, 2026
AC Immune SA (NASDAQ:ACIU) is a Swiss clinical-stage biopharmaceutical company founded in 2003 and headquartered in Lausanne, Switzerland. The company went public on NASDAQ in September 2016. AC Immune specializes in discovering, designing, and developing medicines and diagnostic products for neurodegenerative diseases, particularly those associated with protein misfolding such as Alzheimer's disease, Parkinson's disease, and other related conditions. The company operates through proprietary technology platforms that generate vaccines, antibodies, and small molecules targeting misfolded proteins that accumulate in the brain and cause neurodegeneration.
Similar companies
Latest newsMore news →
AC Immune SA reported a quarterly loss of $0.16 per share, compared with a Zacks Investment Research, Inc. consensus estimate of a $0.22 loss and a $0.20 loss per share a year earlier.2h agoAC Immune initiated the Alzheimer's disease AD4 cohort in the ABATE trial, triggering a $12 million milestone payment from Takeda.91d ago